A pharmaceutical composition comprises；(i) a drug component comprising at least one beclomethasone compound selected from beclomethasone, and the pharmaceutically acceptable derivatives thereof, and at least one long acting beta-2-agonist (LABA)； (ii) a propellant component comprising 1,1-difluoroethane (HFA-152a)； and (iii) glycerol. Most preferably, the composition has less than 5 ppm water. Most preferably, the LABA is formoterol fumarate dihydrate. Preferably, the composition additionally comprises a muscarinic agonist, most preferably； glycopyrronium bromide. Preferably, the composition also comprises a polar excipient； most preferably, ethanol. Preferably, the composition is surfactant-free and also free of acid stabilisers. The composition may be used with a metered dose inhaler (MDI) Also disclosed is a method for improving the stability of a pharmaceutical composition comprising a propellant component, a drug component comprising at least one beclomethasone compound, glycerol and ethanol, said method comprising using a propellant component comprising 1,1-difluoroethane.
